Logo image of SSKN

STRATA SKIN SCIENCES INC (SSKN) Stock Fundamental Analysis

NASDAQ:SSKN - Nasdaq - US86272A3059 - Common Stock - Currency: USD

1.95  0 (0%)

After market: 1.94 -0.01 (-0.51%)

Fundamental Rating

2

Taking everything into account, SSKN scores 2 out of 10 in our fundamental rating. SSKN was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of SSKN have multiple concerns. While showing a medium growth rate, SSKN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SSKN has reported negative net income.
SSKN had a positive operating cash flow in the past year.
In the past 5 years SSKN always reported negative net income.
In multiple years SSKN reported negative operating cash flow during the last 5 years.
SSKN Yearly Net Income VS EBIT VS OCF VS FCFSSKN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

SSKN has a Return On Assets (-26.71%) which is comparable to the rest of the industry.
SSKN's Return On Equity of -342.83% is on the low side compared to the rest of the industry. SSKN is outperformed by 83.42% of its industry peers.
Industry RankSector Rank
ROA -26.71%
ROE -342.83%
ROIC N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
SSKN Yearly ROA, ROE, ROICSSKN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

SSKN has a Gross Margin of 58.44%. This is comparable to the rest of the industry: SSKN outperforms 56.15% of its industry peers.
SSKN's Gross Margin has declined in the last couple of years.
SSKN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
SSKN Yearly Profit, Operating, Gross MarginsSSKN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SSKN has been increased compared to 1 year ago.
The number of shares outstanding for SSKN has been reduced compared to 5 years ago.
SSKN has a worse debt/assets ratio than last year.
SSKN Yearly Shares OutstandingSSKN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SSKN Yearly Total Debt VS Total AssetsSSKN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

SSKN has an Altman-Z score of -9.51. This is a bad value and indicates that SSKN is not financially healthy and even has some risk of bankruptcy.
SSKN has a Altman-Z score of -9.51. This is in the lower half of the industry: SSKN underperforms 78.07% of its industry peers.
A Debt/Equity ratio of 5.71 is on the high side and indicates that SSKN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 5.71, SSKN is doing worse than 90.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.71
Debt/FCF N/A
Altman-Z -9.51
ROIC/WACCN/A
WACC9.81%
SSKN Yearly LT Debt VS Equity VS FCFSSKN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

SSKN has a Current Ratio of 1.05. This is a normal value and indicates that SSKN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.05, SSKN is doing worse than 89.30% of the companies in the same industry.
A Quick Ratio of 0.87 indicates that SSKN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.87, SSKN is doing worse than 84.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.87
SSKN Yearly Current Assets VS Current LiabilitesSSKN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.33% over the past year.
The Revenue has been growing slightly by 3.30% in the past year.
SSKN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.22% yearly.
EPS 1Y (TTM)24.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42%
Revenue 1Y (TTM)3.3%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%0.86%

3.2 Future

The Earnings Per Share is expected to grow by 33.80% on average over the next years. This is a very strong growth
Based on estimates for the next years, SSKN will show a small growth in Revenue. The Revenue will grow by 6.35% on average per year.
EPS Next Y54.06%
EPS Next 2Y33.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.13%
Revenue Next 2Y6.35%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SSKN Yearly Revenue VS EstimatesSSKN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
SSKN Yearly EPS VS EstimatesSSKN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SSKN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SSKN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SSKN Price Earnings VS Forward Price EarningsSSKN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

SSKN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SSKN is cheaper than 72.73% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 22.53
SSKN Per share dataSSKN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as SSKN's earnings are expected to grow with 33.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.8%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SSKN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRATA SKIN SCIENCES INC

NASDAQ:SSKN (8/1/2025, 8:04:24 PM)

After market: 1.94 -0.01 (-0.51%)

1.95

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners29.52%
Inst Owner Change0.08%
Ins Owners3.91%
Ins Owner Change0%
Market Cap8.13M
Analysts85
Price Target9.18 (370.77%)
Short Float %0.26%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.67%
Min EPS beat(2)-271.14%
Max EPS beat(2)-10.2%
EPS beat(4)1
Avg EPS beat(4)-50.91%
Min EPS beat(4)-271.14%
Max EPS beat(4)95.8%
EPS beat(8)2
Avg EPS beat(8)-84.42%
EPS beat(12)5
Avg EPS beat(12)-45.36%
EPS beat(16)8
Avg EPS beat(16)-19.44%
Revenue beat(2)1
Avg Revenue beat(2)-1.84%
Min Revenue beat(2)-8.28%
Max Revenue beat(2)4.61%
Revenue beat(4)3
Avg Revenue beat(4)2.19%
Min Revenue beat(4)-8.28%
Max Revenue beat(4)11.4%
Revenue beat(8)3
Avg Revenue beat(8)-5.33%
Revenue beat(12)6
Avg Revenue beat(12)-1.18%
Revenue beat(16)8
Avg Revenue beat(16)-0.34%
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-26.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-18.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF 18.4
P/B 3.05
P/tB N/A
EV/EBITDA 22.53
EPS(TTM)-2.27
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)0.11
OCFY5.44%
SpS8.06
BVpS0.64
TBVpS-1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.71%
ROE -342.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.44%
FCFM N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score5
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 5.71
Debt/FCF N/A
Debt/EBITDA 20.36
Cap/Depr 21.07%
Cap/Sales 3.3%
Interest Coverage N/A
Cash Conversion 59.09%
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 0.87
Altman-Z -9.51
F-Score5
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)60.99%
Cap/Depr(5y)68.15%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42%
EPS Next Y54.06%
EPS Next 2Y33.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.3%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%0.86%
Revenue Next Year3.13%
Revenue Next 2Y6.35%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year142.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y122.55%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%